Immunology

The Immunology Department at St James’s hospital  runs a number of both investigator-led and industry centered drug trials in Immunology.

Current Trials & Studies
Study NameStudy TitleStudy TypeSponsorSponsor Type
HAE Survey Burden of hereditary angioedema (HAE) and impact on quality of life: A multi-national survey of patients and caregiversObservational-non invasive Takeda Commercial: Industry
EU-COVAT-2 BOOSTAVACAn International Multicentre, Phase 2, Randomised, Adaptive Protocol to determine the need for, optimal timing of and immunogenicity of administering a 4 th homologous mRNA vaccination dose against SARS-CoV-2 in the general population (18+ years) already vaccinated against SARS-CoV-2 Clinical trial (2021-004889-35)EU Horizon 2020 Non-commercial: Academic
HyQviaNon-interventional Post-Authorization Safety Study on the Long-Term Safety of HyQvia in Subjects treated with HyQviaObservational-non invasive (NCT01034969)BaxaltaCommercial: Industry
IOS registryIcatibant Outcome Survey (IOS) registry protocolObservational-non invasive (NCT01034969)ShireCommercial: Industry
ABT in UrticariaHealth through attention based training (ABT) for patients in SJH with urticariaObservational-non invasiveNon-commercial: Academic
Santorini Treatment of High and Very high riSk dyslipidemic pAtients for the PreveNTion of CardiOvasculaR Events in Europe – a MultInatioNal ObservatIonal Study (SANTORINI) Observational-non invasive Daiichi Sankyo Europe GmbH Commercial: Industry
Past Trials & Studies
Study NameStudy TitleStudy TypeSponsorSponsor Type
CDZ OLEAn open-label, non-randomized extension study to evaluate the long term safety, tolerability, efficacy and pharmacokinetics of CDZ173 in patients with APDS/PASLI (Activated phosphoinositide 3-kinase delta syndrome/ p110δ-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency)Clinical Trial (NCT02859727)(2016-000468-41)NovartisCommercial: Industry
CDZAn open-label, non-randomized, within-patient dose-finding study followed by a randomized, subject, investigator and sponsor-blinded placebo controlled study to assess the efficacy and safety of CDZ173 in patients with APDS/PASLI (Activated phosphoinositide 3-kinase delta syndrome/ p110δ-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency)Clinical Trial (NCT02435173) (2014-003876-22)NovartisCommercial: Industry